New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Wang, Fang Fang ^a   Zhu, Li An ^a   Zou, Yu Qiong ^a   Zheng, Hui ^a   Wilson, Alisa ^b   Yang, Cheng De ^a   Shen, Nan ^a   Wallace, Daniel J ^b   Weisman, Michael H ^b   Chen, Shun Le ^a   Lu, Liang Jing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PREDNISOLONE; SMALL INTERFERING RNA; GLUCOCORTICOID; I KAPPA B KINASE; ISOMERASE; MIF PROTEIN, HUMAN;

ADULT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RATING SCALE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; WESTERN BLOTTING; DRUG RESISTANCE; GENETIC TRANSFECTION; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; BLOTTING, WESTERN; DRUG RESISTANCE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; HUMANS; I-KAPPA B KINASE; INTRAMOLECULAR OXIDOREDUCTASES; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84860344211     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3828     Document Type: Article

References (34)

1. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donnelly T, Bucala R. An essential regulatory role for macrophage migrationinhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996, 93:7849-7854. 10.1073/pnas.93.15.7849, 38837, 8755565.
2. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179:1895-1902. 10.1084/jem.179.6.1895, 2191507, 8195715.
3. Greven D, Leng L, Bucala R. Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Targets 2010, 14:253-264. 10.1517/14728220903551304, 20148714.
4. Flaster H, Bernhagen J, Calandra T, Bucala R. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007, 21:1267-1280. 10.1210/me.2007-0065, 17389748.
5. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377:68-71. 10.1038/377068a0, 7659164.
6. Roger T, Chanson AL, Knaup-Reymond L, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eul J Immunol 2005, 35:3405-3413.
7. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004, 31:268-273.
8. Santos L, Hall P, Metz C, Bucala R, Morand EF. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 2001, 123:309-314. 10.1046/j.1365-2249.2001.01423.x, 1905992, 11207663.
9. Leech M, Metz C, Bucala R, Morand EF. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 2000, 43:827-833. 10.1002/1529-0131(200004)43:4<827::AID-ANR13>3.0.CO;2-K, 10765927.
10. Berdeli A, Mir S, Ozkayin N, Serdaroglu E, Tabel Y, Cura AET. Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome. Pediatr Nephrol 2005, 20:1566-1571. 10.1007/s00467-005-1930-9, 16133063.
11. De Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R, Lunt M, Thomson W, Ravelli A, Donn R, Martini A, . British Paediatric Rheumatology Study Group Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003, 48:1398-1407. 10.1002/art.10882, 12746913, British Paediatric Rheumatology Study Group.
12. Aeberli D, Yang Y, Mansell A, Santos L, Leech M, Morand EF. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAPkinase. FEBS Lett 2006, 580:974-981. 10.1016/j.febslet.2006.01.027, 16442105.
13. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994, 12:141-179. 10.1146/annurev.iy.12.040194.001041, 8011280.
14. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996, 87:13-20. 10.1016/S0092-8674(00)81318-5, 8858144.
15. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995, 9:2723-2735. 10.1101/gad.9.22.2723, 7590248.
16. Auphan N, Didonato JA, Rosette C, Helmberg A, Met K. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270:286-290. 10.1126/science.270.5234.286, 7569976.
17. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995, 270:283-286. 10.1126/science.270.5234.283, 7569975.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
19. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640. 10.1002/art.1780350606, 1599520.
20. Seki M, Ushiyama C, Seta N, Abe K, Fukazawa T, Asakawa J, Takasaki Y, Hashimoto H. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum 1998, 41:823-830. 10.1002/1529-0131(199805)41:5<823::AID-ART8>3.0.CO;2-#, 9588733.
21. van den Akker EL, Russcher H, van Rossum EF, Brinkmann AO, de Jong FH, Hokken A, Pols HA, Koper JW, Lamberts SW. Glucocorticoid receptor polymorphism affects transrepression but not transactivation. J Clin Endocrinol Metab 2006, 91:2800-2803. 10.1210/jc.2005-2119, 16684836.
22. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002, 109:649-657. 10.1067/mai.2002.122465, 11941315.
23. Kozaci DL, Chernajovsky Y, Chikanza IC. The differential expression of corticosteroid receptor isoforms in corticosteroid-resistant and -sensitive patients with rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:579-585.
24. Loke TK, Mallett KH, Ratoff J, O'Connor BJ, Ying S, Meng Q, Soh C, Lee TH, Corrigan CJ. Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients. J Allergy Clin Immunol 2006, 118:368-375. 10.1016/j.jaci.2006.04.055, 16890760.
25. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PW, Weir DG, Kelleher D. High multidrug resistance (p-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000, 118:279-288. 10.1016/S0016-5085(00)70210-1, 10648456.
26. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug resistance induced by p-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 2008, 67:380-388.
27. Ishiguro Y, Ohkawara T, Sakuraba H, Yamagata K, Hiraga H, Yamaguchi S, Fukuda S, Munakata A, Nakane A, Nishihira J. Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. Clin Immunol 2006, 120:335-341. 10.1016/j.clim.2006.05.010, 16807115.
28. Leng L, Wang W, Roger T, Merk M, Wuttke M, Calandra T, Bucala R. Glucocorticoid-induced MIF expression by human CEM T cells. Cytokine 2009, 48:177-185. 10.1016/j.cyto.2009.07.002, 2767395, 19646897.
29. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999, 20:435-459. 10.1210/er.20.4.435, 10453354.
30. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000, 14:2314-2329. 10.1101/gad.827900, 316928, 10995388.
31. Daun JM, Cannon JG. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IκBα. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1043-R1049.
32. Amin MA, Haas CS, Zhu K, Mansfield PJ, Kim MJ, Lackowski NP, Koch AE. Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFκB. Blood 2006, 107:2252-2261. 10.1182/blood-2005-05-2011, 1472703, 16317091.
33. Sreih A, Ezzeddine R, Leng L, Lachance A, Yu G, Mizue Y, Subrahmanyan L, Pons-Estel BA, Abelson AK, Gunnarsson I, Svenungsson E, Cavett J, Glenn S, Zhang L, Montgomery R, Perl A, Salmon J, Alarcon-Riquelme ME, Harley JB, Bucala R. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum 2011, 63:3942-3951. 10.1002/art.30624, 22127710.
34. Leng L, Chen L, Fan J, Greven D, Arjona A, Du X, Austin D, Kashqarian M, Yin Z, Huang XR, Lan HY, Lolis E, Nikolic-Paterson D, Bucala R. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol 2011, 186:527-538. 10.4049/jimmunol.1001767, 3124407, 21106847.